| Chronic systemic pesticide exposure reproduces features of Parkinson's disease R Betarbet, TB Sherer, G MacKenzie, M Garcia-Osuna, AV Panov, ... Nature neuroscience 3 (12), 1301-1306, 2000 | 4620 | 2000 |
| Unified Huntington's disease rating scale: reliability and consistency K Kieburtz, JB Penney, P Como, N Ranen, I Shoulson, A Feigin, ... Movement disorders 11 (2), 136-142, 1996 | 2011 | 1996 |
| Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines AV Panov, CA Gutekunst, BR Leavitt, MR Hayden, JR Burke, ... Nature neuroscience 5 (8), 731-736, 2002 | 1254 | 2002 |
| Mechanism of toxicity in rotenone models of Parkinson's disease TB Sherer, R Betarbet, CM Testa, BB Seo, JR Richardson, JH Kim, ... Journal of Neuroscience 23 (34), 10756-10764, 2003 | 1225 | 2003 |
| Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation TB Sherer, JH Kim, R Betarbet, JT Greenamyre Experimental neurology 179 (1), 9-16, 2003 | 980 | 2003 |
| A highly reproducible rotenone model of Parkinson's disease JR Cannon, V Tapias, HM Na, AS Honick, RE Drolet, JT Greenamyre Neurobiology of disease 34 (2), 279-290, 2009 | 862 | 2009 |
| Animal models of Parkinson's disease R Betarbet, TB Sherer, JT Greenamyre Bioessays 24 (4), 308-318, 2002 | 823 | 2002 |
| Alternative excitotoxic hypotheses RL Albin, JT Greenamyre Neurology 42 (4), 733-733, 1992 | 780 | 1992 |
| An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered α-synuclein metabolism and oxidative damage TB Sherer, R Betarbet, AK Stout, S Lund, M Baptista, AV Panov, ... Journal of Neuroscience 22 (16), 7006-7015, 2002 | 742 | 2002 |
| Excitatory amino acids and Alzheimer's disease JT Greenamyre, AB Young Neurobiology of aging 10 (5), 593-602, 1989 | 645 | 1989 |
| α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease R Di Maio, PJ Barrett, EK Hoffman, CW Barrett, A Zharikov, A Borah, X Hu, ... Science translational medicine 8 (342), 342ra78-342ra78, 2016 | 619 | 2016 |
| Parkinson's--divergent causes, convergent mechanisms JT Greenamyre, TG Hastings Science 304 (5674), 1120-1122, 2004 | 562 | 2004 |
| A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease Huntington Study Group Neurology 57 (3), 397-404, 2001 | 504 | 2001 |
| NMDA receptor losses in putamen from patients with Huntington's disease AB Young, JT Greenamyre, Z Hollingsworth, R Albin, C D'Amato, ... Science 241 (4868), 981-983, 1988 | 503 | 1988 |
| N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking AL Orr, S Li, CE Wang, H Li, J Wang, J Rong, X Xu, PG Mastroberardino, ... Journal of Neuroscience 28 (11), 2783-2792, 2008 | 488 | 2008 |
| The role of environmental exposures in neurodegeneration and neurodegenerative diseases JR Cannon, JT Greenamyre Toxicological Sciences 124 (2), 225-250, 2011 | 469 | 2011 |
| Autoradiographic characterization of N-methyl-D-aspartate-, quisqualate-and kainate-sensitive glutamate binding sites. JT Greenamyre, JM Olson, JB Penney, AB Young Journal of Pharmacology and Experimental Therapeutics 233 (1), 254-263, 1985 | 466 | 1985 |
| Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives AHV Schapira, CW Olanow, JT Greenamyre, E Bezard The Lancet 384 (9942), 545-555, 2014 | 456 | 2014 |
| LRRK2 activation in idiopathic Parkinson’s disease R Di Maio, EK Hoffman, EM Rocha, MT Keeney, LH Sanders, ... Science translational medicine 10 (451), eaar5429, 2018 | 450 | 2018 |
| Glutamate and Parkinson’s disease F Blandini, RHP Porter, JT Greenamyre Molecular neurobiology 12, 73-94, 1996 | 445 | 1996 |
Laurie H SandersAssociate Professor of Neurology, Duke University Medical Center在 duke.edu 的电子邮件经过验证
